Type your tag names separated by a space and hit enter

Acarbose in the prevention of cardiovascular disease and hypertension in patients with impaired glucose tolerance

Evidence Summaries

Level of Evidence = A

Acarbose is effective in the prevention of cardiovascular events and hypertension in patients with impaired glucose tolerance.

In an international, multicentre trial 1 , 1429 patients with a mean age of 54.5 years and BMI 30.9 were randomized to receive either acarbose 100 mg 3 times a day or placebo. Decreasing prostprandial hyperglycemia with acarbose was associated with a 2.5% absolute risk reduction and a 49% relative risk reduction in the development of cardiovascular events (HR 0.51, 95% CI 0.28 to 0.95), and a 5.3% absolute risk reduction and 34% relative risk reduction in the incidence of new cases of hypertension (HR 0.66, 95% CI 0.49 to 0.89). The risk reduction was no influenced by adjusting for major risk factors.

References

1. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003 Jul 23;290(4):486-94.  [PMID:12876091]


Copyright © 2017 Duodecim Medical Publications Limited.
Acarbose in the prevention of cardiovascular disease and hypertension in patients with impaired glucose tolerance is a sample topic from the Evidence-Based Medicine Guidelines.

To view other topics, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.

Citation

"Acarbose in the Prevention of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/455922/all/Acarbose_in_the_prevention_of_cardiovascular_disease_and_hypertension_in_patients_with_impaired_glucose_tolerance.
Acarbose in the prevention of cardiovascular disease and hypertension in patients with impaired glucose tolerance. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/455922/all/Acarbose_in_the_prevention_of_cardiovascular_disease_and_hypertension_in_patients_with_impaired_glucose_tolerance. Accessed March 23, 2019.
Acarbose in the prevention of cardiovascular disease and hypertension in patients with impaired glucose tolerance. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/455922/all/Acarbose_in_the_prevention_of_cardiovascular_disease_and_hypertension_in_patients_with_impaired_glucose_tolerance
Acarbose in the Prevention of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2019 March 23]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/455922/all/Acarbose_in_the_prevention_of_cardiovascular_disease_and_hypertension_in_patients_with_impaired_glucose_tolerance.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Acarbose in the prevention of cardiovascular disease and hypertension in patients with impaired glucose tolerance ID - 455922 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/455922/all/Acarbose_in_the_prevention_of_cardiovascular_disease_and_hypertension_in_patients_with_impaired_glucose_tolerance PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -